MBRX

Moleculin BiotechF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$0.75

Analysis reference price unavailable

Analysis 2026-10-16 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$0.30

Analysis reference price unavailable

Analysis 2026-10-16 · RankAlpha Sentiment Codex

B-

Bear case

35%

Probability

Target price

$0.08

Analysis reference price unavailable

Analysis 2026-10-16 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-16

AI commentary

The completed Part A enrollment improves milestone visibility, but the listing determination and financing horizon keep the balance of risks negative. No trustworthy post-release price-reaction attribution, analyst revisions, options data, short-interest figure, employee score, or sufficient social coverage was supplied; zero-valued fields denote unavailable data, not neutral readings.

RankAlpha Sentiment Codex - 2026-10-16

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-12-31catalystNasdaq listing decisionHigh impact

Nasdaq issued a minimum-bid-price delisting determination without an ordinary compliance period because of a prior reverse split. Moleculin said it intended to request a hearing, which, if timely, would stay suspension pending a decision; the filing does not establish that continued listing was granted. [#SEC-8K-2026-09-18] SEC filing

2027-03-31eventMIRACLE Part A readoutHigh impact

Moleculin reported that Part A enrollment closed with 89 patients and guided to a comprehensive first-quarter 2027 readout. The earlier 45-patient remission signal is preliminary; the larger readout could materially strengthen or weaken the Annamycin thesis. [#SEC-8K-2026-09-29] SEC filing

2027-03-31catalystFunding for the next trial phaseHigh impact

The August results release said cash, including $9.3 million raised after quarter-end, was expected to fund operations into first-quarter 2027. Additional financing or a collaboration may be needed to sustain development beyond the Part A readout; timing and terms are unconfirmed. [#PR-EARNINGS-2026-08-14] SEC confirmation of the results release

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-16 • Updated nightlySource: Internal modelMethodology